Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.

David A NielsenRobrina WalkerDavid P GrahamEllen M NielsenSara C HamonMaureen HillhouseDikla Shmueli-BlumbergWilliam B LawsonKathy Shores-WilsonBeverlyn D Settles-ReavesJohn RotrosenMadhukar H TrivediAndrew J SaxonWalter LingThomas R Kosten

Published in: European journal of clinical pharmacology (2022)

These results suggest that PDYN variants may identify patients who are best suited to treatment with XR-NTX plus buprenorphine for cocaine use disorder pharmacotherapy.

Keyphrases

end stage renal disease
copy number
newly diagnosed
peritoneal dialysis
genome wide
gene expression
replacement therapy
genome wide identification